Endoron Medical
Endoron is developing a catheter-based endograft stapling solution to overcome the challenges associated with the sealing and fixation of endografts used for the minimally invasive repair of abdominal aortic aneurysms.
The EndoStapling solution, designed to avoid highly invasive, high-mortality open surgery, is meant to secure an endograft's fixation and to improve sealing mechanisms. About 400,000 new patients in the U.S. and Europe are diagnosed with AAA disease every year, with 42% presenting complex anatomies.
Founded in 2019, Endoron Medical builds on an invention from Prof. Ron Karmeli (Hadassah Hospital, Jerusalem), who is co-founder and Chief Medical Officer of the Company.
Cécile Dupont, Senior Associate and Program Director at Sofinnova Partners MS Start III Fund, is joining the Endoron management team to bring greater operational and strategic support.
Sector
Medical Devices
Strategies
MD Start
Status
Live
Website
endoronmedical.com
Related News
SofinnovaCapital
The Sofinnova Capital Strategy is our flagship fund, investing as founding or lead investor in early-stage biopharma and medtech start-ups developing groundbreaking therapeutic technologies.
SofinnovaMD Start
The Sofinnova MD Start Strategy is our in-house medtech accelerator focused on creating and launching early-stage medtech companies through hands-on company building.
SofinnovaCrossover
The Sofinnova Crossover Strategy invests in growth-stage biotech and medtech companies that have clinically validated their technologies and are preparing for commercialization.
SofinnovaIndustrial Biotech
Our Industrial Biotech Strategy invests in early-stage sustainable companies across the agriculture, chemicals, food and materials sectors.
SofinnovaTelethon
The Sofinnova Telethon Strategy makes early-stage investments in leading Italian science for the benefit of patients around the world.
SofinnovaDigital Medicine
Our Digital Medicine Strategy backs early-stage techbio and healthtech start-ups at the intersection of biology, data, and computation.
SofinnovaBiovelocita
The Sofinnova Biovelocita Strategy is our biotech accelerator, partnering with leading research organizations to create and build European biotech start-ups.